CFM
AKRO

Catalyst Funds Management’s Akero Therapeutics AKRO Stock Holding History

Catalyst Funds Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-800
Closed -$23K – 333
2024
Q3 		$23K Buy
+800
New +$20.9K 0.01% 1053

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Catalyst Funds Management's AKRO Position: Q4 2024 in Review

Catalyst Funds Management sold out of Akero Therapeutics (AKRO) in Q4 2024, closing a stake of 800 shares — an estimated $23K sold.

Catalyst Funds Management first reported a position in AKRO in Q3 2024 and held it in 1 quarter. The position peaked at $23K in Q3 2024. 191 funds tracked by Wall St. Rank hold AKRO as of Q4 2024.

  • Catalyst Funds Management reported no remaining Akero Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 800 Akero Therapeutics shares in Q4 2024, an estimated $23K.
  • Catalyst Funds Management first reported a position in Akero Therapeutics in Q3 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Akero Therapeutics position peaked at $23K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.